OSeac

OSeac consolidates gene expression and clinical follow-up data from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) to perform survival analyses and evaluate prognostic biomarkers in esophageal adenocarcinoma (EAC).

Key Features:

• Centralized Data Repository: Consolidates gene expression data and clinical follow-up information from TCGA and GEO comprising 198 EAC cases for survival analysis.
• Survival Analysis Methodology: Generates Kaplan Meier (KM) survival plots, calculates hazard ratios (HR), and performs log rank tests to assess prognostic significance of genes in EAC.
• Validation with Known Biomarkers: Validates results using established prognostic biomarkers DKK3, CTO1, and TXNIP.

Scientific Applications:

• Prognostic biomarker identification: Identifies genes associated with patient survival in EAC through survival analysis.
• Biomarker validation: Provides a framework to validate candidate prognostic biomarkers such as DKK3, CTO1, and TXNIP.
• Patient risk stratification: Facilitates stratification of EAC patients into risk groups based on gene expression and survival associations.
• Gene-gene interaction exploration: Supports exploration of gene-gene relationships and their associations with prognosis.
• Translational research support: Informs development of treatment strategies based on genetic profiles and survival correlations.

Methodology:

Data consolidation from TCGA and GEO followed by Kaplan Meier (KM) survival plotting, hazard ratio (HR) calculation, and log rank testing, with validation using biomarkers DKK3, CTO1, and TXNIP.